Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Co-morbidity in prostate cancer.

M P Wirth1, M Froehner

  • 1Department of Urology, University Clinics 'Carl Gustav Carus', Technical University of Dresden, Dresden, Germany.

The Aging Male : the Official Journal of the International Society for the Study of the Aging Male
|June 9, 2006
PubMed
Summary

Prostate cancer screening reveals many elderly men have severe co-morbidities. These conditions, not cancer, often determine survival, impacting clinical trial design for localized prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Development and treatment of localized/systemic BCGitis : Retrospective studies in direct comparison to mitomycin C].

Der Urologe. Ausg. A·2018
Same author

[Evaluation of the decision aid "Entscheidungshilfe Prostatakrebs" from the patients' view : Results from the first three months].

Der Urologe. Ausg. A·2016
Same author

Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study.

Prostate cancer and prostatic diseases·2016
Same author

Robots drive the German radical prostatectomy market: a total population analysis from 2006 to 2013.

Prostate cancer and prostatic diseases·2016
Same author

[German urologists are open to new ways of making wise decisions].

Der Urologe. Ausg. A·2016
Same author

[Focal therapy is also not chamomile tea : Comment on Apfelbeck et al.: "Focal therapy of prostate cancer in Germany"].

Der Urologe. Ausg. A·2016

Area of Science:

  • Oncology
  • Geriatrics
  • Public Health

Background:

  • Prostate cancer is the most common cancer diagnosed in the US, particularly affecting elderly men.
  • The increasing prevalence of prostate cancer in older populations highlights the importance of co-morbid conditions.
  • Assessing co-morbidity is crucial for understanding survival outcomes in prostate cancer patients.

Purpose of the Study:

  • To evaluate the significance of co-morbid conditions in newly diagnosed prostate cancer patients.
  • To determine the impact of concomitant diseases on the survival of elderly men with prostate cancer.
  • To inform clinical trial design by considering age and co-morbidity stratification.

Main Methods:

  • Review of existing co-morbidity assessment scores applied to prostate cancer patients.
  • Analysis of survival data in relation to the severity of co-morbid conditions.
  • Consideration of patient demographics, focusing on elderly males and localized prostate cancer.

Main Results:

  • Patients in their eighth decade with severe co-morbidity are likely to die from other causes.
  • Localized prostate cancer in elderly men with severe co-morbidities may not be the primary cause of mortality.
  • Life expectancy is not significantly compromised in patients with one controlled concomitant disorder.

Conclusions:

  • Co-morbid conditions significantly influence survival in elderly prostate cancer patients.
  • Clinical trials for localized prostate cancer require stratification for age and co-morbidity.
  • Management strategies for prostate cancer patients with controlled co-morbidities remain a subject of debate.

Related Experiment Videos